Clinical Trials Logo

Renal Failure, Chronic clinical trials

View clinical trials related to Renal Failure, Chronic.

Filter by:

NCT ID: NCT04204005 Completed - Clinical trials for Renal Failure Chronic

Probiotics and Low Protein Diet in Advanced Chronic Kidney Disease

ProLowCKD
Start date: March 13, 2017
Phase: N/A
Study type: Interventional

Here the investigators will perform a double-blinded randomized placebo-controlled clinical trial to evaluate the synergic effect of low protein diet and prebiotics in reducing the microbial inflammatory uremic toxins.

NCT ID: NCT03949036 Completed - Clinical trials for Kidney Transplant; Complications

Comparison of Two Different Preload Targets of Stroke Volume Variation During Kidney Transplantation

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

The investigators sought to compare the effect of two preload targets of stroke volume variation of ≤6% and ≤12% on the postoperative renal function in patients undergoing living donor kidney transplantation. Goal-directed fluid therapy will be performed in both groups to maintain adequate stroke volume, stroke volume variation, mean arterial pressure (or systemic vascular resistance) during kidney transplantation. Only the preload target for giving crystalloid during surgery will be different between groups.

NCT ID: NCT03904836 Completed - Renal Dialysis Clinical Trials

Tobramycin Administered at the Beginning of Dialysis

ESRD
Start date: January 31, 2019
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate whether the administration of a full tobramycin dose (5 mg/kg) during the first 30 minutes of a hemodialysis session provides favorable pharmacokinetic parameters in subjects with end-stage renal disease who are suspected or has been diagnosed with Gram-negative rod-type infection. It is anticipated that the administration of a single 5 mg/kg dose of tobramycin during the first 30 minutes of a hemodialysis session will achieve an optimal ratio of maximum tobramycin concentration to minimal inhibitory concentration (Cmax/CMI) of 8 to 10 while limiting the accumulation (trough < 2 mg/L before the next hemodialysis session) in end-stage renal disease subjects requiring intermittent hemodialysis sessions.

NCT ID: NCT03781726 Completed - Hepatitis C Clinical Trials

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

MYTHIC
Start date: April 10, 2019
Phase: Phase 4
Study type: Interventional

Open label multi center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.

NCT ID: NCT03778944 Recruiting - Anesthesia Clinical Trials

Enhancing Renal Graft Function During Donor Anesthesia

Start date: December 20, 2018
Phase: N/A
Study type: Interventional

Renal transplantation is now recognized as the treatment of choice for patients with end-stage renal disease. An optimum anesthetic regimen should enhance the function and perfusion of the transplanted kidney. The aim of this study is to assess & compare the effectiveness of 3 different modalities in this respect: Mannitol, Dopamine and adequate hydration.

NCT ID: NCT03658876 Completed - Anemia Clinical Trials

Predictors of Response to Iron and Erythropoietin Stimulating Agents

PRIME
Start date: June 3, 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment. A positive outcome following treatment was defined as an uptitration of haemoglobin by greater than 5g/l within 2 months. The study evaluated the participants response to treatment against the clinical and biochemical information collected prior to treatment being received.

NCT ID: NCT03436368 Active, not recruiting - Anesthesia Clinical Trials

Continuous Spinal Anesthesia in Renal Transplantation

Start date: February 20, 2018
Phase: N/A
Study type: Interventional

Renal transplantation is now recognized as a treatment of choice for patients with end-stage renal disease. An adequate anesthetic technique should achieve hemodynamic stability and enhance perfusion of the transplanted kidney. The aim of this study is to assess the use & effects of continuous spinal anesthesia for kidney transplantation recipients, compared with balanced general anesthesia.

NCT ID: NCT03246984 Completed - Kidney Diseases Clinical Trials

VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ

VALUE
Start date: September 7, 2017
Phase: N/A
Study type: Interventional

This is a prospective single arm study enrolling patients who are scheduled for creation of a new Brachiocephalic or Radiocephalic AV fistula. Up to 80 patients will be enrolled, 50 with upper arm AV fistula and 30 with forearm AV fistula. All patients will be implanted with the VasQ device, a subcutaneous arteriovenous conduit support for vascular access. The follow up period in this study will be for a duration of 12 months, with follow up visits scheduled at 1, 3, 6, 9, and 12 months.

NCT ID: NCT03093740 Withdrawn - Hepatitis C Clinical Trials

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Open label single center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.

NCT ID: NCT02332811 Completed - Clinical trials for Renal Failure Chronic

An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients

TOSCANA
Start date: October 2013
Phase: Phase 3
Study type: Interventional

Primary Objective: Evaluate the reduction in serum phosphorus from baseline to end of study with Sevelamer carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD) patients both on haemodialysis and not on dialysis Secondary Objective: Evaluate the safety on the basis of adverse events, changes in laboratory values and vital signs from baseline (Day 0) to Day 56 (End of treatment/ End of Study)